A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Agents that promote the excretion of urine through their effects on kidney function.
Physicians who serve in a medical and administrative capacity as head of an organized medical staff and who also may serve as liaison for the medical staff with the administration and governing board.
Schedules of medical and nursing procedures, including diagnostic tests, medications, and consultations designed to effect an efficient, coordinated program of treatment. (From Mosby's Medical, Nursing & Allied Health Dictionary, 4th ed)
Confidence in or reliance on a person or thing.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
Attitudes of personnel toward their patients, other professionals, toward the medical care system, etc.

Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. (1/73)

The thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) is the major pathway for salt reabsorption in the apical membrane of the mammalian distal convoluted tubule. When expressed in Xenopus laevis oocytes, rat TSC exhibits high affinity for both cotransported ions, with the Michaelis-Menten constant (K(m)) for Na(+) of 7.6 +/- 1.6 mM and for Cl(-) of 6.3 +/- 1.1 mM, and Hill coefficients for Na(+) and Cl(-) consistent with electroneutrality. The affinities of both Na(+) and Cl(-) were increased by increasing concentration of the counterion. The IC(50) values for thiazides were affected by both extracellular Na(+) and Cl(-). The higher the Na(+) or Cl(-) concentration, the lower the inhibitory effect of thiazides. Finally, rTSC function is affected by extracellular osmolarity. We propose a transport model featuring a random order of binding in which the binding of each ion facilitates the binding of the counterion. Both ion binding sites alter thiazide-mediated inhibition of transport, indicating that the thiazide-binding site is either shared or modified by both Na(+) and Cl(-).  (+info)

Atenolol and bendrofluazide in hypertension. (2/73)

The effect of atenolol, a new beta-1-adrenergic receptor blocking agent, was studied in a double-blind cross-over trial in 24 carefully selected hypertensive outpatients. After a four-week run-in period on matching placebo each patient received atenolol 200 mg/day, atenolol 400 mg/day, a combination of atenolol 200/mg day with bendrofluazide 5 mg/day, and bendrofluazide 5 mg/day alone, according to a random sequence. Atenolol at either dose produced a significantly greater reduction in all blood pressure levels except standing systolic pressure than bendrofluazide alone. There was no statistically significant difference between the effects of the two atenolol doses on either blood pressure or pulse rate. The addition of bendrofluazide to atenolol resulted in a further significant lowering of the blood pressure. A significant effect of thiazide on weight was noted. The study shows that atenolol, a cardioselective beta-blocker of similar potency to propranolol in animals but without membrane-stabilizing or partial agonist acitivity, is an effective and well-tolerated hypotensive agent.  (+info)

Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. (3/73)

Despite normal indices of left ventricular (LV) chamber function, patients with LV hypertrophy (LVH) due to hypertension are thought to have depressed midwall systolic shortening compared with normotensives. The aims of the present study were (1) to confirm this observation and (2) to assess the effects of antihypertensive therapy that cause regression of LVH on LV systolic function assessed at both the midwall and endocardium. Thirty-eight previously untreated hypertensive subjects with LVH underwent echocardiography and were compared with 38 normotensive control subjects. Comparisons between the group with LVH and the control group revealed no significant differences in cardiac output (4. 32+/-0.23 versus 4.55+/-0.21 L/min), ejection fraction (62.5+/-2% versus 66.4+/-1.07%), or endocardial fractional shortening (34.5+/-1.45% versus 37.0+/-0.82%), but shortening assessed at the midwall was significantly less in the group with LVH (17.9+/-1.11% versus 21.6+/-0.63%, P<0.01). Subsequently, 32 patients with uncontrolled hypertension (24 previously untreated and 8 on existing antihypertensive therapy) underwent treatment with ramipril, with the addition of felodipine and bendrofluazide if required, to reduce blood pressure to <140/90 mm Hg. These 32 patients underwent echocardiography at baseline, after blood pressure control, and after an additional 6 months of tight blood pressure control. Good blood pressure control was achieved after 6 months compared with baseline (143/86+/-2.8/1.4 versus 174/103+/-4.1/1.9 mm Hg; P<0.01) with significant regression of LV mass index (124+/-3.4 versus 145+/-3.8 g/m(2), P<0.01). LV fractional shortening assessed at the midwall improved with regression of LVH (21.9+/-0.84 and 18.7+/-1. 19%, P<0.05), with posttreatment midwall shortening being similar to that of the normal control subjects evaluated in the first study. Hypertensive patients with LVH have depressed midwall systolic shortening despite normal indices of LV chamber function. Regression of LVH after good blood pressure control improved midwall shortening to normal levels.  (+info)

Electrical potential difference, sodium absorption and potassium secretion by the human rectum during carbenoxolone therapy. (4/73)

The transmucosal electrical potential difference (pd) and the sodium and potassium net fluxes were measured in the rectum of subjects taking carbenoxolone. There was a rise in transmucosal pd persisting throughout treatment in all subjects which was accompanied by an increase in sodium absorption and potassium secretion. Comparison of the pd changes produced by carbenoxolone with those due to the mineralocorticoid 9-alpha-fluorocortisol showed that carbenoxolone had about 1/1000th the potency on a weight basis and the two drugs appeared to be additive in their effects. Topical instillation of carbenoxolone into the rectum produced an elevation of pd which persisted for three days. Amiloride and bendrofluazide did not interfere with these actions of carbenoxolone but spironolactone abolished them. One patient who developed fluid retention and hypokalaemia had a rectal pd similar to that of the other patients who had no side effects.  (+info)

Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. (5/73)

BACKGROUND: Vascular endothelial dysfunction may predict future atherosclerosis. Hence, an antihypertensive agent that reverses endothelial dysfunction and lowers blood pressure might improve the prognosis of patients with hypertension. We hypothesized that nebivolol, a vasodilating beta-blocker, could improve endothelial dysfunction. We tested this hypothesis by comparing the effects of nebivolol and atenolol on endothelial function. METHODS AND RESULTS: Twelve hypertensive patients with a mean ambulatory blood pressure of 154+/-7/97+/-10 mm Hg were randomized after a 2-week placebo run-in period (baseline) in a double-blind, crossover fashion to 8-week treatment periods with either 5 mg of nebivolol with 2.5 mg of bendrofluazide or 50 mg of atenolol with 2.5 mg of bendrofluazide. Forearm venous occlusion plethysmography and intra-arterial infusions of acetylcholine and N(G)-monomethyl-L-arginine (L-NMMA) were used to assess stimulated and basal endothelium-dependent nitric oxide release, respectively. Sodium nitroprusside was used as an endothelium-independent control. Nebivolol/bendrofluazide and atenolol/bendrofluazide each lowered the clinic blood pressure to the same extent (132+/-7/82+/-6 and 132+/-9/83+/-8 mm Hg, respectively; P<0.001 from baseline). The vasodilatory response to acetylcholine was significantly increased with nebivolol/bendrofluazide (maximum percentage change in forearm blood flow [mean+/-SEM], 435+/-27%, P<0.001) but not with atenolol/bendrofluazide. Similarly, the endothelium-dependent vasoconstrictive response to L-NMMA was significantly improved only with nebivolol treatment (percentage change in forearm blood flow, -54+/-5%; P<0.001). The response to sodium nitroprusside was not different between treatments, suggesting that the endothelium-independent pathway was unaffected. CONCLUSIONS: Nebivolol/bendrofluazide increased both stimulated and basal endothelial nitric oxide release, whereas for the same degree of blood pressure control, atenolol/bendrofluazide had no effect on nitric oxide bioactivity. Thus, nebivolol may offer additional vascular protection in treating hypertension.  (+info)

Role of sodium depletion in acute antidiuretic effect of bendroflumethiazide in rats with nephrogenic diabetes insipidus. (6/73)

The mechanisms underlying the acute antidiuretic response to bendroflumethiazide (BFTZ; 0.25 mg/h for 3 h) in rats with nephrogenic diabetes insipidus (NDI) was investigated. NDI was induced in conscious chronically instrumented female Wistar rats either by chronic lithium administration (40-60 mmol Li/kg of diet for 4 weeks) or by acute infusion of V2 antagonist OPC-31260 (0.2 mg/h). Renal clearance experiments were performed in conscious rats instrumented with permanent catheters. During experiments total body water content was held constant by i.v. replacement of urine production (V) with 150 mM glucose. One group in addition received i.v. replacement of urinary sodium losses. In both models of NDI, BFTZ-induced antidiuresis was associated with a decrease in the delivery of tubular fluid to the distal nephron, as measured by lithium clearance (C(Li)). Both the antidiuresis and the decrease in C(Li) could be prevented by sodium replacement. BFTZ did not affect distal water handling as measured by V/C(Li). BFTZ did not induce antidiuresis in normal rats with water diuresis. It is concluded that in rats with NDI, thiazide-induced antidiuresis can be entirely explained by a fall in distal delivery of tubular fluid related to sodium depletion. This contrasts the response in rats with central diabetes insipidus, where thiazides in addition increase distal water reabsorption.  (+info)

Monitoring one-year compliance to antihypertension medication in the Seychelles. (7/73)

OBJECTIVE: To examine the compliance to medication among newly diagnosed hypertensive patients screened from the general population of the Seychelles, a rapidly developing country. METHODS: Among the 1067 participants to a population-based survey for cardiovascular risk factors, hypertension was discovered in 50 (previously unaware of having hypertension and having blood pressure > or = 160/95 mmHg over 3 visits). These 50 patients were placed on a daily one-pill regimen of medication (bendrofluazide, atenolol, or a combination of hydrochlorothiazide and atenolol) and compliance to the regimen was assessed over 12 months using electronic pill containers. Satisfactory compliance was defined as taking the medication on 6 or 7 days a week on average (which corresponds to a mean compliance level of > or = 86%). FINDINGS: In the first month, fewer than half (46%) of the new hypertension patients achieved satisfactory compliance, and only about one-quarter (26%) achieved this level by the twelfth month. Compliance was better among the 23 participants who regularly attended medical follow-up, with nearly three-quarters of these patients (74%) achieving satisfactory compliance during the first month and over one-half (55%) by the twelfth month. There was a direct association between mean 12-month compliance level and having a highly skilled occupation; having good health awareness; and regularly attending medical appointments. In contrast, there was an inverse relationship between mean compliance level and heavy drinking. CONCLUSION: The low proportion of people selected from the general population who were capable of sustaining satisfactory compliance to antihypertension medication may correspond to the maximum effectiveness of medication interventions based on a screening and treatment strategy in the general population. The results stress the need for both high-risk and population approaches to improve hypertension control.  (+info)

Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). (8/73)

To investigate the relationship between soluble markers of platelet, endothelial and rheological function, and target organ damage and their response to intensified management in a population of middle-age hypertensive patients at high risk of cardiovascular complications, we studied 382 consecutive patients (308 men; mean age, 63 years, SD 8) along with 60 normotensive controls free of cardiovascular disease. Patients were divided into those with target organ damage (TOD; n=107) and those free of end-organ damage. Plasma levels of soluble P-selectin (sP-sel), a marker of platelet activation, and von Willebrand factor (vWF), an index of endothelial damage/dysfunction (both enzyme-linked immunosorbent assay), and the rheological indices fibrinogen, plasma viscosity, hematocrit, platelet, and white cell count were measured. In 53 patients, variables were further measured after 6 months of intensified cardiovascular risk management. Patients with TOD had significantly higher vWF, 137 (SD 33) versus 125 (SD 33) IU/dL (P=0.002,) and a greater proportion of smokers, 31% versus 16% (P=0.002). There were no statistically significant differences in plasma viscosity, fibrinogen, hematocrit, white blood cell count, platelet count, or sP-sel between the 2 subgroups. In multivariate analysis, vWF was a significant independent predictor for TOD. After 6 months of intensified management in 53 patients who entered the trial, there were significant reductions in systolic blood pressure, total cholesterol, hematocrit, plasma viscosity, sP-sel, and vWF (all P<0.01) but no significant change in fibrinogen. In conclusion, there is a relationship between TOD and endothelial damage/dysfunction in hypertension. Intensified management results in improvements in hemorheology, endothelial and platelet function.  (+info)

Bendroflumethiazide is a diuretic medication, which means it helps the body get rid of excess salt and water by increasing urine production. It is primarily used to treat high blood pressure and edema (swelling) caused by various medical conditions.

The drug works by inhibiting the reabsorption of sodium and chloride ions in the distal convoluted tubule of the kidney, which leads to increased water excretion. This results in a decrease in blood volume and, consequently, reduced blood pressure.

Bendroflumethiazide is available under various brand names, such as Aprinox, Corrida, and Natrilix. It's important to note that this medication should only be taken under the supervision of a healthcare professional, as it can have side effects and interact with other medications.

Sodium chloride symporter inhibitors are a class of pharmaceutical agents that block the function of the sodium chloride symporter (NCC), which is a protein found in the kidney's distal convoluted tubule. The NCC is responsible for reabsorbing sodium and chloride ions from the filtrate back into the bloodstream, helping to regulate electrolyte balance and blood pressure.

Sodium chloride symporter inhibitors work by selectively binding to and blocking the NCC, preventing it from transporting sodium and chloride ions across the cell membrane. This leads to increased excretion of sodium and chloride in the urine, which can help lower blood pressure in patients with hypertension.

Examples of sodium chloride symporter inhibitors include thiazide diuretics such as hydrochlorothiazide and chlorthalidone, which have been used for many years to treat hypertension and edema associated with heart failure and liver cirrhosis. These medications work by reducing the amount of sodium and fluid in the body, which helps lower blood pressure and reduce swelling.

It's worth noting that while sodium chloride symporter inhibitors can be effective at treating hypertension, they can also cause side effects such as electrolyte imbalances, dehydration, and increased urination. As with any medication, it's important to use them under the guidance of a healthcare provider and to follow dosing instructions carefully.

Chlorthalidone is a diuretic medication, which is a type of drug that helps the body get rid of excess salt and water by increasing urine production. It is a type of sulfonamide, and it works by blocking the reabsorption of sodium and chloride in the distal convoluted tubules of the kidneys, which leads to increased excretion of these ions and water in the urine.

Chlorthalidone is used to treat hypertension (high blood pressure) and edema (fluid retention) associated with various medical conditions, such as heart failure, cirrhosis, and kidney disease. It may be used alone or in combination with other medications to achieve better blood pressure control.

Like all medications, chlorthalidone can cause side effects, including electrolyte imbalances, dehydration, dizziness, headache, muscle cramps, and gastrointestinal disturbances. It is important to take this medication as directed by a healthcare provider and to report any bothersome or persistent symptoms promptly.

Diuretics are a type of medication that increase the production of urine and help the body eliminate excess fluid and salt. They work by interfering with the reabsorption of sodium in the kidney tubules, which in turn causes more water to be excreted from the body. Diuretics are commonly used to treat conditions such as high blood pressure, heart failure, liver cirrhosis, and kidney disease. There are several types of diuretics, including loop diuretics, thiazide diuretics, potassium-sparing diuretics, and osmotic diuretics, each with its own mechanism of action and potential side effects. It is important to use diuretics under the guidance of a healthcare professional, as they can interact with other medications and have an impact on electrolyte balance in the body.

Physician executives are medical doctors who hold senior leadership positions within healthcare organizations, such as hospitals, health systems, or insurance companies. They are responsible for making strategic decisions that affect the overall operations and financial performance of the organization, while also ensuring high-quality patient care.

Physician executives may have titles such as Chief Medical Officer (CMO), Chief Executive Officer (CEO), or Vice President of Medical Affairs. Their duties can include developing clinical policies and procedures, overseeing medical staff affairs, managing risk and compliance issues, and leading quality improvement initiatives.

To become a physician executive, one typically needs to have significant experience as a practicing physician, as well as additional training in leadership, management, and business administration. Many physician executives hold advanced degrees such as an MBA or a Master's in Health Administration.

Critical pathways, also known as clinical pathways or care maps, are specialized treatment plans for specific medical conditions. They are designed to standardize and improve the quality of care by providing evidence-based guidelines for each stage of a patient's treatment, from diagnosis to discharge. Critical pathways aim to reduce variations in care, promote efficient use of resources, and enhance communication among healthcare providers. These pathways may include recommendations for medications, tests, procedures, and follow-up care based on best practices and current research evidence. By following critical pathways, healthcare professionals can ensure that patients receive timely, effective, and coordinated care, which can lead to better outcomes and improved patient satisfaction.

I'm sorry for any confusion, but "trust" is a general concept and not a medical term with a specific definition. It can be used in various contexts, including healthcare relationships between patients and healthcare providers. In this context, trust refers to the confidence and reliance that patients have on the competence, professionalism, honesty, and integrity of their healthcare providers.

However, if you're looking for a medical term related to "trust," there is a psychological concept called "interpersonal trust" which can be assessed using the "Trust Scale." Interpersonal trust refers to an individual's general willingness to rely on and be vulnerable to others across various situations. This concept might be relevant in some medical or healthcare research contexts, particularly those involving patient-provider communication, adherence to treatment plans, and therapeutic relationships.

Biological models, also known as physiological models or organismal models, are simplified representations of biological systems, processes, or mechanisms that are used to understand and explain the underlying principles and relationships. These models can be theoretical (conceptual or mathematical) or physical (such as anatomical models, cell cultures, or animal models). They are widely used in biomedical research to study various phenomena, including disease pathophysiology, drug action, and therapeutic interventions.

Examples of biological models include:

1. Mathematical models: These use mathematical equations and formulas to describe complex biological systems or processes, such as population dynamics, metabolic pathways, or gene regulation networks. They can help predict the behavior of these systems under different conditions and test hypotheses about their underlying mechanisms.
2. Cell cultures: These are collections of cells grown in a controlled environment, typically in a laboratory dish or flask. They can be used to study cellular processes, such as signal transduction, gene expression, or metabolism, and to test the effects of drugs or other treatments on these processes.
3. Animal models: These are living organisms, usually vertebrates like mice, rats, or non-human primates, that are used to study various aspects of human biology and disease. They can provide valuable insights into the pathophysiology of diseases, the mechanisms of drug action, and the safety and efficacy of new therapies.
4. Anatomical models: These are physical representations of biological structures or systems, such as plastic models of organs or tissues, that can be used for educational purposes or to plan surgical procedures. They can also serve as a basis for developing more sophisticated models, such as computer simulations or 3D-printed replicas.

Overall, biological models play a crucial role in advancing our understanding of biology and medicine, helping to identify new targets for therapeutic intervention, develop novel drugs and treatments, and improve human health.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

A questionnaire in the medical context is a standardized, systematic, and structured tool used to gather information from individuals regarding their symptoms, medical history, lifestyle, or other health-related factors. It typically consists of a series of written questions that can be either self-administered or administered by an interviewer. Questionnaires are widely used in various areas of healthcare, including clinical research, epidemiological studies, patient care, and health services evaluation to collect data that can inform diagnosis, treatment planning, and population health management. They provide a consistent and organized method for obtaining information from large groups or individual patients, helping to ensure accurate and comprehensive data collection while minimizing bias and variability in the information gathered.

The "attitude of health personnel" refers to the overall disposition, behavior, and approach that healthcare professionals exhibit towards their patients or clients. This encompasses various aspects such as:

1. Interpersonal skills: The ability to communicate effectively, listen actively, and build rapport with patients.
2. Professionalism: Adherence to ethical principles, confidentiality, and maintaining a non-judgmental attitude.
3. Compassion and empathy: Showing genuine concern for the patient's well-being and understanding their feelings and experiences.
4. Cultural sensitivity: Respecting and acknowledging the cultural backgrounds, beliefs, and values of patients.
5. Competence: Demonstrating knowledge, skills, and expertise in providing healthcare services.
6. Collaboration: Working together with other healthcare professionals to ensure comprehensive care for the patient.
7. Patient-centeredness: Focusing on the individual needs, preferences, and goals of the patient in the decision-making process.
8. Commitment to continuous learning and improvement: Staying updated with the latest developments in the field and seeking opportunities to enhance one's skills and knowledge.

A positive attitude of health personnel contributes significantly to patient satisfaction, adherence to treatment plans, and overall healthcare outcomes.

"Bendroflumethiazide". NHS. 29 August 2018. Retrieved 2018-09-29. "Bendroflumethiazide Side Effects". Drugs.com. Retrieved 2018- ... Bendroflumethiazide may also impair the user's motor skills, therefore it is important to be aware of its effects and to take ... Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload ... Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal ...
Bendroflumethiazide Holdrege CT, Babel RB, Cheney LC (1959). "Synthesis of Trifluoromethylated Compounds Possessing Diuretic ...
Cyclothiazide Hydrochlorothiazide Bendroflumethiazide Whitehead CW, Traverso JJ, Sullivan HR, Marshall FJ (1961). "Diuretics. V ...
Some benzothiadiazine derivatives are used as pharmaceutical drugs, including: bendroflumethiazide chlorothiazide cyclothiazide ...
Drugs which reduce blood levels of potassium such as diuretics like furosemide and bendroflumethiazide should also be avoided ...
... bendroflumethiazide MeSH D03.438.174.261 - chlorothiazide MeSH D03.438.174.261.476 - hydrochlorothiazide MeSH D03.438.174.261. ...
... bendroflumethiazide MeSH D02.886.590.700.135.261 - chlorothiazide MeSH D02.886.590.700.135.261.476 - hydrochlorothiazide MeSH ... bendroflumethiazide MeSH D02.886.655.500.261 - chlorothiazide MeSH D02.886.655.500.261.476 - hydrochlorothiazide MeSH D02.886. ...
2005 landmark trial that compared the effects of the established therapy of the combination of atenolol and bendroflumethiazide ...
Bendopa bendroflumethiazide (INN) BeneFix (Wyeth/Pfizer) Benemid benethamine penicillin (INN) benexate (INN) Benfluorex (INN) ...
... epitizide hydrochlorothiazide and chlorothiazide bendroflumethiazide methyclothiazide polythiazide Thiazide-like diuretics: ...
C03AA01 Bendroflumethiazide C03AA02 Hydroflumethiazide C03AA03 Hydrochlorothiazide C03AA04 Chlorothiazide C03AA05 Polythiazide ... combinations C03AB01 Bendroflumethiazide and potassium C03AB02 Hydroflumethiazide and potassium C03AB03 Hydrochlorothiazide and ... Cyclopenthiazide and potassium-sparing agents C03EA12 Metolazone and potassium-sparing agents C03EA13 Bendroflumethiazide and ...
"Bendroflumethiazide". NHS. 29 August 2018. Retrieved 2018-09-29. "Bendroflumethiazide Side Effects". Drugs.com. Retrieved 2018- ... Bendroflumethiazide may also impair the users motor skills, therefore it is important to be aware of its effects and to take ... Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload ... Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal ...
Toxicity. It cannot be excluded that bendroflumethiazide is toxic, due to the lack of data.. Risk. Risk of environmental impact ... Bendroflumethiazide has previously been included in screening programs and measured in the aquatic environment in Region ... Persistence. It cannot be excluded that bendroflumethiazide is persistent, due to the lack of data.. Bioaccumulation. It cannot ... Risk of environmental impact of bendroflumethiazide cannot be excluded, due to the lack of environmental toxicity. ...
Evidence-based interaction details between Bendroflumethiazide, Rauwolfia Serpentina (brand name(s): Rauzide) and Spearmint, ... Still looking for more information about combining Bendroflumethiazide, Rauwolfia Serpentina and Spearmint? Ask Dr. Brian ... Spearmint - Rauzide (Bendroflumethiazide, Rauwolfia Serpentina) Interaction. Herbal: Spearmint Also Known As: Mentha spicata, ... There were no interactions found between Bendroflumethiazide, Rauwolfia Serpentina and Spearmint. This does not mean the ...
Detailed drug Information for Orphenadrine w/A.C.. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
... bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; ...
bendroflumethiazide. Minor (1)bendroflumethiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/ ... bendroflumethiazide. bendroflumethiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance ...
The first stop for professional medicines advice
Providing accredited 3rd party API GMP audit reports of manufacturing sites around the globe • Audited by Europes first inspection body for APIs • Diapharm
BENDROFLUMETHIAZIDE. Drug Indication. Drug Administration Route. Drug #3. Date the patient began taking the drug and date the ...
A simple HPLC procedure is described for the determination of bendroflumethiazide (BMFT) in pharmaceutical formulations and ... Photodegradation and Photstability Studies of Bendroflumethiazide in Pharmaceutical Formulations and Urine Samples by Micellar ... Photodegradation and Photostability Studies of Bendroflumethiazide (BFMT) in Pharmaceutical Formulations and Urine Samples by ... the authors present a simple high performance liquid chromatographic procedure for the determination of bendroflumethiazide ( ...
These include diuretics like hydrochlorothiazide, chlortalidone and bendroflumethiazide. Add to that, patients can also try ...
Bendroflumethiazide. *Relieves hypertension. *Available from our UK regulated pharmacy. View Treatment Bisoprolol. *Regulates ...
Common examples are indapamide and bendroflumethiazide.. Possible side effects include dizziness when standing up, increased ...
The majesty of the gods is so terrifying, there are real gods in the how does bendroflumethiazide lower blood pressure world, ...
Bendroflumethiazide 50 = Benemid 50 = Bentyl 54 = Blocadren 50 = Brethine 49 = Butal 49 = Butisol NOTE: All medications given ... bendroflumethiazide) Saluron (hydroflumethiazide) Spironazide Spironolactone Thiazide Water pill (no brand given) 45 ...
keywords = "Albuminuria, Amino Acids, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Bendroflumethiazide, ... antihypertensive treatment was replaced with bendroflumethiazide. After 2-months wash-out, patients were treated randomly with ... antihypertensive treatment was replaced with bendroflumethiazide. After 2-months wash-out, patients were treated randomly with ... antihypertensive treatment was replaced with bendroflumethiazide. After 2-months wash-out, patients were treated randomly with ...
... events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide ...
The 2017 Annual Report of The Anti-Doping Authority the Netherlands, the independent NADO of the Netherlands.
Diuretic-thiazide (bendroflumethiazide).. -- ACE inhibitor- enalapril, lisinopril, ramipril.. -- ARB-losartan, valsartan, ...
Bendroflumethiazide Erectile Dysfunction The first mansion of the Great Song Dynasty Kaifu was Photography ed sheeran Mansion ... and he doesnt quite Bendroflumethiazide erectile dysfunction of Shes words But others clearly knew the meaning of Shes words ...
Hypertension affects approximately 75 million adults in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. See the image below.
... bendroflumethiazide, atenolol, (+)-4-{3-{[2-(1-hydroxycyclohexyl)ethyl]-4-oxo-2-thiazolidinyl.intg.propyl }benzoic acid, ... bendroflumethiazide, chlorothalidone, chlorothiazide, clonidine, crypteanamine acetates and cryptenamine tannates, deserpidine ...
Hirsutism is a condition where women grow excess hair. You can buy prescription hair removal creams at euroClinix® ✓ Free Next-Day Delivery
Bendroflumethiazide. Benzonatate. Benzoyl_peroxide. Benztropine_Mesylate. Betamethasone. Bevacizumab. Bicalutamide. Bupropian. ...
A commonly used example of this type of diuretic is bendroflumethiazide. Loop diuretics inhibit sodium and chloride ion ...
5] EMC, Bendroflumethiazide tablets, https://www.medicines.org.uk/emc/product/5726/pil. Accessed 24th January, 2019. ...
  • Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. (ndclist.com)
  • There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets.Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. (ndclist.com)
  • These considerations may guide selection of therapy.Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. (ndclist.com)
  • Bendroflumethiazide, formerly bendrofluazide, trade name Aprinox, is a thiazide diuretic used to treat hypertension. (wikipedia.org)
  • The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation). (wikipedia.org)
  • Risk of environmental impact of bendroflumethiazide cannot be excluded, due to the lack of environmental toxicity. (janusinfo.se)
  • Common adverse effects: feeling dizzy due to orthostatic hypotension dry mouth or feeling thirsty nausea stomach ache fatigue diarrhea or constipation joint pain due to gout Rare adverse effects: thrombocytopenia agranulocytosis photosensitivity rash pancreatitis chronic kidney disease Bendroflumethiazide is known to have an adverse interaction with alcohol. (wikipedia.org)
  • The majesty of the gods is so terrifying, there are real gods in the how does bendroflumethiazide lower blood pressure world, and when I offend does lowering your cholesterol lower your blood pressure this god in the future, I don't know where to hide. (jewishledger.com)
  • Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. (wikipedia.org)
  • In a double-masked randomised crossover trial of 52 hypertensive type 2 diabetic patients, antihypertensive treatment was replaced with bendroflumethiazide. (regionh.dk)
  • It is also known that bendroflumethiazide suppresses the production of breast milk. (wikipedia.org)
  • Nadolol and bendroflumethiazide tablets for oral administration combine two antihypertensive agents: nadolol, a nonselective beta-adrenergic blocking agent, and bendroflumethiazide, a thiazide diuretic-antihypertensive. (nih.gov)
  • Each tablet contains 40 mg or 80 mg nadolol combined with 5 mg bendroflumethiazide. (nih.gov)
  • In this article, the Veterans Administration Cooperative Study Group reported that nadolol, a beta-blocker, and bendroflumethiazide, a diuretic, appeared to be safe and effective antihypertensive agents with minimal side effects. (nih.gov)
  • They noted that nadolol was more effective in white patients, while bendroflumethiazide worked better in black patients. (nih.gov)
  • 18. Effects of furosemide and bendroflumethiazide on saliva flow rate and composition. (nih.gov)
  • No information is available on the amount of bendroflumethiazide in breastmilk. (nih.gov)
  • Intense diuresis with large doses of bendroflumethiazide can decrease breastmilk production, especially during the neonatal period. (nih.gov)
  • His blood pressure in the clinic was 186/104 mmHg, despite treatment with bendroflumethiazide, enalapril and felodipine. (basicmedicalkey.com)
  • Used to treat arterial hypertension, heart failure and edema, Bendroflumethiazide is a diuretic that increases the excretion of sodium and chloride. (axanopharmainternational.com)
  • Bendroflumethiazide Chlorothiazide Chlorthalidone Hydrochlorothiazide Hydroflumethiazide Indapamide Methyclothiazide Metolazone Other medicines may also contain thiazide. (nih.gov)
  • The woman's previous history was unremarkable apart from a diagnosis of mild hypertension treated with bendroflumethiazide. (ncl.ac.uk)
  • She had a history of hypertension which was being treated with lisinopril atorvastatin and bendroflumethiazide and had been taking lansoprazole for 18 months for dyspepsia. (pkc-inhibitor.com)
  • Den vanliga dosen för Neo Naclex(Bendrofluazide) är 5 mg till 10 mg, normalt The usual dose for Neo Naclex(Bendrofluazide) is 5mg to 10mg, normally taken adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): Swaggers ahead of the bendrofluazide Peter's, overexposed describe inköp att beställa cialis 2.5mg 5mg 10mg 20mg 40mg nederländerna underdeveloped bendroflumethiazide as required, in the Anglo-Scandinavian. (firebaseapp.com)
  • Shorter-acting diuretics in low doses are preferred over bendroflumethiazide. (nih.gov)
  • Bendroflumethiazide has been used to suppress lactation in oral doses of 5 mg twice daily for 5 days, and in doses of 10 mg in the morning and 5 mg in the afternoon. (nih.gov)
  • AprinoxSumalNaturetinHidromensTensofluxPrecyclanNeoNaClexSalur Patients received 5 mg bendroflumethiazide twice daily. (firebaseapp.com)